Observational studyJournal of neuro-oncology2022

Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?

Roberta Rudà et al.PubMed ↗Publisher ↗

No numbers read from the abstract.